<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT138809042770N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2010-10-12</date_registration>
      <primary_sponsor>Kurdistan University of Medical Sciences, vice chancellor for research</primary_sponsor>
      <public_title>Effect of moderate and high resistant training on the inflammatory markers and cardiovascular risk factors in non-athlete students</public_title>
      <acronym></acronym>
      <scientific_title>Effect of moderate and high resistant training on the inflammatory markers and cardiovascular risk factors in non-athlete students</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2008-01-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/2612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research.</study_design>
      <phase>N/A</phase>
      <hc_freetext>cardiovascular risk factor and inflammatory markers.</hc_freetext>
      <i_freetext>Intervention 1: Subjects in high intensitiy resistance group undergwent exercise regime consist of three sessions of resistance training per week for six consecutive weeks. In each session they did three sets of 4-6 repetitions at intensity of 80-90% of 1-RM (one repetition maximum). Intervention 2: Subjects in moderate intensitiy resistance group undergwent exercise regime consist of three sessions of resistance training per week for six consecutive weeks. In each session they did three sets of 10-12 repetitions at intensity of 45-55% of 1-RM (one repetition maximum). Intervention 3: Subjects of the control group did not do any regular physical activities during the period of study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Slahadin Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Physiology, School of Medicine</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-13446</zip>
        <telephone>+98 87 1662 1399</telephone>
        <email>slahadin@yahoo.com; slahadin@gmail.com; slahadin@muk.ac.ir</email>
        <affiliation>Kurdistan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Slahadin Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Physiology, School of Medicine</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-13446</zip>
        <telephone>+98 87 1662 1399</telephone>
        <email>slahadin@yahoo.com; slahadin@gmail.com; slahadin@muk.ac.ir</email>
        <affiliation>Kurdistan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: Healthy young students with no previous record of any specific drug use and routine regular exercises during the last two years.    &#13;
        Exclusion: Unhealthy, Doing regular exercise during the last two years.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>26 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I70</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Subjects in high intensitiy resistance group undergwent exercise regime consist of three sessions of resistance training per week for six consecutive weeks. In each session they did three sets of 4-6 repetitions at intensity of 80-90% of 1-RM (one repetition maximum).</i_keyword>
      <i_keyword>Subjects in moderate intensitiy resistance group undergwent exercise regime consist of three sessions of resistance training per week for six consecutive weeks. In each session they did three sets of 10-12 repetitions at intensity of 45-55% of 1-RM (one repetition maximum).</i_keyword>
      <i_keyword>Subjects of the control group did not do any regular physical activities during the period of study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Triglyceride, High-density lipoprotein, Low-density lipoprotein,Total cholesterol ,ApoA, ApoB. Timepoint: 6 weeks. Method of measurement: by collecting venous blood and measuring serum levels of related variables before and at the end of the study.</prim_outcome>
      <prim_outcome>Lipoprotein Lipase. Timepoint: 6 weeks. Method of measurement: by collecting venous blood before and at the end of study and measuring serum levels using LPL kit.</prim_outcome>
      <prim_outcome>Interleukin1 and Interleukin 6. Timepoint: 6 weeks. Method of measurement: by collecting venous blood before and at the end of study and measuring serum levels of related factors using Enzyme-linked immunosorbent assay (ELISA).</prim_outcome>
      <prim_outcome>Hs-CRP (high-sensitivity CRP) and fibrinogen. Timepoint: 6 weeks. Method of measurement: by collecting venous blood before and at the end of study and measuring serum levels using related kits.</prim_outcome>
      <prim_outcome>Body Mass Index. Timepoint: 6 weeks. Method of measurement: bybody composition analyzer (Biospase CO, Ltd).</prim_outcome>
      <prim_outcome>Waist Hip Ratio. Timepoint: 6 weeks. Method of measurement: By measuring Hip and Waist circumferences by measuring tape.</prim_outcome>
      <prim_outcome>Systolic and diastolic Blood pressure. Timepoint: 6 weeks. Method of measurement: sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kurdistan University of Medical Sciences, vice chancellor for research</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-03-17</approval_date>
        <contact_name>Kurdistan University of Medical Sciences</contact_name>
        <contact_address>vice chancellor for research, Kurdistan University of Medical Sciences sanandaj  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
